Celcuity
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Minnesota, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
16305 36th Ave N Ste 100, Minneapolis, M...Phone Number
(763) 392-0767Website
www.celcuity.comRevenue
-Stock Symbol
CELCIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
2
2
2
1
About Celcuity
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis.Explore more
Celcuity Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celcuity your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Celcuity launches new products
Website visits: Recent activity has been detected on your website
Celcuity, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Celcuity has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Celcuity
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Celcuity recently announced quarterly report
Funding: Get notified immidiatlly once Celcuity has new funding data
Check out if Celcuity is spiking on competitors!
Click to see if Celcuity had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Celcuity
Compare insights from companies similar to Celcuity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Celcuity is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Celcuity is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Celcuity.
Celcuity financials insights
Gather financial insights about Celcuity, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Multiple Rounds
$31.1M
2020
Debt
$350K
2021
Stock Offering
$24M
2024
Debt
$62M
Celcuity Tech Stack
A closer look at the technologies used by Celcuity
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Product Launch, Pharmaceuticals
Person-Based
Stake & Stock Ownership, Finance
Celcuity News & Media
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:Celcuity (CELC): Landmark Approval Collides With A Costly Launch
On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company’s history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone […]Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally adCelcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
Celcuity Inc. (CELC) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDTCompany ParticipantsJodi Sievers - Head of Investor Relations & Corporate...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Celcuity
Sign Up For FreeTo access detailed company insights
Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy. The company's therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can ident... Read More
